Detalhe da pesquisa
1.
A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine.
Cephalalgia
; 44(4): 3331024241232944, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38659334
2.
Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adults.
Cephalalgia
; 44(2): 3331024231219505, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38366390
3.
Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
J Headache Pain
; 25(1): 57, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627638
4.
A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants.
Cephalalgia
; 43(6): 3331024231179131, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37282507
5.
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials.
Cephalalgia
; 43(2): 3331024221141686, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36739511
6.
Effects of rimegepant 75 mg daily on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female participants.
Headache
; 63(5): 652-662, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37140071
7.
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Lancet
; 397(10268): 51-60, 2021 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338437
8.
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
N Engl J Med
; 381(2): 142-149, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291516
9.
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Headache
; 62(9): 1153-1163, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36239038
10.
Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Headache
; 61(6): 906-915, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34021585
11.
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Lancet
; 394(10200): 737-745, 2019 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31311674
12.
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Headache
; 60(8): 1734-1742, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32799325
13.
Testing rimegepant for migraine-time to revise the trial design? - Authors' reply.
Lancet
; 395(10241): 1901-1902, 2020 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32563365
14.
Pain Freedom at 2-8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response.
Headache
; 60(10): 2611-2612, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249583
15.
Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States.
J Pain Res
; 17: 1805-1814, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38799274
16.
The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study.
Clin Pharmacol Drug Dev
; 13(1): 37-44, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37904724
17.
A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants.
Clin Pharmacol Drug Dev
; 13(5): 465-473, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38174905
18.
No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults.
Clin Transl Sci
; 17(3): e13727, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38440916
19.
Concentration-QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval.
CPT Pharmacometrics Syst Pharmacol
; 2024 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38812357
20.
A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Br J Clin Pharmacol
; 75(1): 136-45, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22616739